3 Absurdly Cheap Growth Stocks to Buy in 2026

The piece highlights three attractively valued growth names — AbbVie, Micron Technology and Adobe — trading at forward P/Es below ~16 and exhibiting PEGs under 1. AbbVie (forward P/E just under 16, PEG ~0.40) reported $44.5B revenue for the first nine months (up 8% YoY) and $10.5B operating earnings, with a large R&D-backed pipeline and a prior forecast of high single-digit growth. Micron (forward P/E 11, PEG 0.6) has seen ~250% share appreciation over 12 months but generated $11.9B net income on $42.3B revenue over the past four quarters (28% margin) and is refocusing away from consumer toward B2B/data-center AI demand. Adobe (forward P/E ~14, PEG just under 1) posted fiscal 2025 revenue of $23.8B (up 11% YoY) and $7.1B net income (up 28%) with ~90% gross margins, suggesting room to defend pricing amid rising AI competition.

Analysis

Market structure: AI-driven data-center spending is the clear winner (Micron, NVDA suppliers, ASML/AMAT in capex), while consumer-memory and commoditized photo-editing startups face pressure. Valuation breathers (ABBV forward P/E ~16 vs S&P 22; MU P/E 11; ADBE P/E 14) suggest rotation into high-profit, cash-generative names rather than frothy multiple expansion. Tightness in DRAM/NAND supply could sustain pricing for 6–18 months but is cyclical — a 20–30% inventory correction would quickly reverse MU’s pricing power.

Risks: Tail outcomes include a 40%+ cyclic drawdown in memory if hyperscaler AI spend pauses, a regulatory hit to pharma (AbbVie) from biosimilar acceleration, or AI/content legal rulings that compress Adobe pricing power. Immediate (days) risk centers on upcoming earnings/guide; short-term (1–6 months) on inventory/capex signals; long-term (2–5 years) on AbbVie R&D/readouts and Adobe’s AI competitive moat. Hidden dependency: Micron’s free-cash-flow is concentrated in a handful of hyperscalers (if top 3 clients cut orders, revenue swing >20%).

Trade implications: Favor tactical long exposure to MU (conviction on AI demand) sized 2–4% with disciplined hedges; ADBE is a defensive growth buy (1–3%) given 90% gross margins — use covered calls to monetize. ABBV is a stable 2–3% income-growth anchor while monitoring 6–12 month pipeline catalysts. Use pair trades (long MU / short INTC dollar-neutral) to isolate memory vs CPU cyclicality and 3–12 month call spreads on MU to express upside with defined cost.

Contrarian angles: The market may be understating Adobe’s pricing leverage and subscription stickiness — downside seems limited absent a fundamental churn event. Conversely, MU’s 250% YTD move already prices strong execution; a 15–25% pullback would be the cleaner entry. AbbVie’s low PEG (~0.4) discounts R&D risk; reprice positions around Phase 3 readouts. Historical parallel: 2016 memory cycle rebound shows fast upside but equally fast reversals — plan exits at 15–25% adverse moves.

Key Decisions for Investors

• Establish a 3% long position in Micron (MU) within the next 2 weeks; hedge with a 1-year 25% OTM protective put or buy a 9–12 month 20% OTM call spread (pay <3% premium) if bullish; add another 1–2% on a pullback >10%; target 12–18 month horizon, stop-loss at -25%.
• Initiate a 1.5–2% long position in Adobe (ADBE) now and sell 3–6 month covered calls 8–12% OTM to generate income; for asymmetric upside, buy one 12-month 15–20% OTM LEAP call as a 0.5% notional kicker; reassess after next quarterly (within 45 days) for AI product cadence and churn metrics.
• Buy a 2% core position in AbbVie (ABBV) as an income/growth holding and protect with a 6–12 month 5–10% OTM put if pipeline binary risk is unacceptable; plan to re-evaluate following any Phase 3 readouts or FDA decisions within 90–180 days and trim to 1% if guidance deteriorates.
• Enter a dollar‑neutral pair trade: long MU / short INTC sized so net portfolio exposure = 2% (e.g., $100k long MU, $100k short INTC) with a 6–12 month horizon to capture memory/server secular vs client CPU weakness; close if relative performance diverges >15% in either direction.